Zentalis Selects 400mg QD 5:2 Dose, Q1 Cash at $212M
ZNTL•Zentalis Pharmaceuticals ended Q1 2026 with $211.8 million in cash, funding operations into late 2027 and supports execution of DENALI and ASPENOVA trials. The company selected a 400mg QD 5:2 dose for its azenosertib monotherapy pivotal study and dosed the first patient in the Phase 3 ASPENOVA confirmatory trial.
1. Financial Results and Runway
Zentalis reported $211.8 million in cash, cash equivalents and marketable securities as of March 31, 2026, providing funding into late 2027 to support key milestones including the DENALI Part 2 topline readout and ASPENOVA trial activities.
2. Pivotal Dose Selection for Azenosertib
In April 2026 the company selected a 400mg once-daily on a 5-days-on, 2-days-off schedule as the pivotal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer based on interim DENALI Part 2a data showing a differentiated response rate and favorable safety profile.
3. Phase 3 ASPENOVA Trial Initiation
In May 2026 Zentalis dosed the first patient in the ASPENOVA confirmatory Phase 3 trial, which will randomize approximately 420 Cyclin E1-positive PROC patients to azenosertib monotherapy versus investigator’s choice of single-agent chemotherapy.
4. Upcoming Milestones and Expansion Plans
DENALI Parts 2b and 2c are enrolling with topline results expected by year-end 2026 to support an accelerated approval pathway, while MUIR Part 2 dose expansion and pre-commercial launch preparations are underway to broaden azenosertib’s development and market readiness.
